We found that the prophylactic or therapeutic application of the TLR4/TLR9 agonist complex differentially regulated Th1 responses and subsequent tumor cell death by activating IFNγ/STAT1 signaling (in the case of prophylactic treatment) or by activating STAT3 (in the case of therapeutic treatment), which is responsible for the different efficacy against tumor metastasis. This evidence concerns the gene STAT3 and neoplasm.